MINDSET 2 - A Study to Evaluate KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The trial is testing if the medications KarXT + KarX-EC can improve cognition and global functioning in people with mild to Alzheimer's Disease compared to placebo.
This study has been approved by the St Vincent's Health Human Research Ethics Committee (ERM: 120813, SAGE: 2025/PID00272).
Participation
People who meet the following criteria may be eligible to participate;
- Aged 60 - 85 years
- Have a diagnosis of mild or moderate Alzheimer's dementia
- have a study partner able to attend each appointment
- have no other neurological condition
The medication being tested is an oral tablet. The trial goes for 24 weeks and then there is an optional Open Label Extension (where everyone gets the medication - no placebo) for 24 weeks. Participants will have an MRI, blood tests, and cognitive testing as part of the trial.
Participant duration
24 weeks
Available to people living in
VIC
Study begins
Thursday, 19 February 2026
Study ends
Saturday, 19 December 2026
Contact
To find out more about this study, contact:
Laura Margison
Austin Health
mcru.recruitment@austin.org.au
Austin Repatriation Hospital 300 Waterdale road, Ivanhoe, 3079 , VIC
